In Vitro in Vivo NBTXR3

2019 – ASCO – NBTXR3 induces antitumor immune response

Congress Abstracts, In Vitro in Vivo NBTXR3, In Vivo

Radiotherapy (RT) can prime an anti-tumor immune response. Unfortunately, this response rarely generates total tumor destruction and abscopal effect. When activated by RT, intratumorally (IT) administered hafnium oxide nanoparticles (NBTXR3) locally increase radiation dose deposit and tumor cell death compared to RT alone. We hypothesized that NBTXR3 + RT could enhance the anti-tumor immune response, both in mice and humans. […]

2018 – ASCO – NBTXR3 generates an anti-tumor immune response

Congress Abstracts, In Vivo

The enclosed abstract was presented at the 13th Journées cancéropole Grand Sud-Ouest at Poitiers. The abstract Hafnium oxide nanoparticles as an emergent promising treatment for solid tumors describes how hafnium oxide nanoparticles were designed at the nanoscale in the form of crystalline 50nm-particles to efficiently absorb ionizing radiation and increase the radiation dose deposited – “hot spots” of energy deposit – from within the tumor cells for efficient cell killing. […]

2018 – OncoRad – NBXTR3 Abscopal Effect

Congress Abstracts, In Vitro in Vivo NBTXR3, In Vivo

Recent results of a phase II/III in locally advanced Soft Tissue Sarcoma patients demonstrated clinical benefits of intratumorally injected HfO2-NP activated by radiotherapy compared to radiotherapy alone, validating their first-in-class mode of action. In addition, animal studies have reported that HfO2-NP+RT can induce an abscopal effect, where RT alone cannot. […]

2018 – AACR – Activation of the cGAS-STING pathway by NBTXR3

Congress Abstracts, In Vitro, In Vitro in Vivo NBTXR3

Recent studies reported that radiotherapy could activate the cGAS-STING pathway, which plays a fundamental role in the immune response to cytoplasmic DNA, by activation of the transcriptional factor IRF3, leading to expression of interferon-beta. Moreover, cGAS-STING activation appears to be an important component for tumor resident Antigen-Presenting Cells activation, a crucial step for induction of CD8+ T cell response against tumor derived antigens. […]

2017 – Abstract – 35th CFS – Hafnium Oxide Nanoparticles: An Emergent Promising Treatment for Solid Tumors

Congress Abstracts, In Vitro, In Vitro in Vivo NBTXR3

Hafnium oxide nanoparticles: an emergent promising treatment for solid tumors To improve tumor response, radiotherapy (RT) has been combined with chemical agents, radiosensitizers and monoclonal antibodies. However, the complexity of these associations in terms of pharmacology, local control, clinical outcome benefits or patient quality of life underlines the need for the development of new therapeutic approaches. […]

2017 – Abstract Conference Immunotherapy Radiotherapy Combinations NYC

Congress Abstracts, In Vitro, In Vitro in Vivo NBTXR3, In Vivo

Hafnium oxide, an electron-dense material, was designed at the nanoscale to increase the radiation dose deposited from within the cancer cells: “Hot spot” of energy deposit where the nanoparticles are when exposed to radiation therapy (RT). Preclinical studies have demonstrated increase of cancer cells killing in vitro and marked antitumor efficacy in vivo with presence of these nanoparticles […]

2017 – Abstract SITC Conference Maryland – Non Clinical

Congress Abstracts, In Vitro in Vivo NBTXR3, In Vivo

2017 – Abstract AACR-EORTC-NCI

Congress Abstracts, In Vitro in Vivo NBTXR3, In Vivo

Between 70 to 90% of patient have "cold" tumors, i.e. devoid or poorly infiltrated by immune cells, rendering inoperative their treatment by immune checkpoint inhibitors. To allow these patients to benefit from these therapies, it is fundamental to prime an antitumor immune response. […]

2017 – Immunotherapy Workshop

Congress Abstracts, In Vitro in Vivo NBTXR3, In Vivo

Radiotherapy (RT) has proven its ability to function like an in-situ vaccine, showing potential for successful combination with immunotherapeutic agents. Hafnium oxide nanoparticle (HfO2-NP), undergoing clinical trials for enhancing RT, was designed as high electron density material at the nanoscale. HfO2-NPs are taken up by cancer cells and, when exposed to RT, locally increase the radiation dose deposit, triggering more cancer cells death when compared to RT. We hypothesized that HfO2-NP+RT could trigger an enhanced immune response when compared to RT, both in preclinical and clinical settings.

2017 – AACR Abstract – NBTXR3 combination with cisplatin in vivo and in vitro

Congress Abstracts, In Vitro, In Vitro in Vivo NBTXR3, In Vivo

Combination of NBTXR3 and cisplatin has been evaluated in vitro and in vivo. No specific toxicity was observed for the cells exposed only to NBTXR3. For the combined treatment, a marked and enhanced cell destruction when compared to the single agent. In vivo, NBTXR3 combined with low dose of cisplatin delayed tumor growth when compared to single agent CDDP in combination with RT. NBTXR3 is intended to be injected in the tumors. Spilling in the circulation may occur during product administration or, as expected, during tumor destruction, leading to steady trapping of NPs in the reticulo-endothelial system (liver and spleen). Clinically, it is unknown whether patients, previously treated with NPs, may show toxic signs when NPs are exposed (activation) to diagnosis imaging (computed tomography(CT)) of the liver.

Abstracts in this section cover In Vitro and In Vivo data of NBTXR3. In Vitro means that NBTXR3 was studied in cells outside their normal biological context. In Vivo refers to tests of NBTXR3 in animals.